Epigenetic regulators in Acute Myeloid Leukemia and Myelodysplastic Syndromes

Combined epigenetic targets in Acute Myeloid Leukemia (AML) and Myelodysplastic Syndromes (MDS) refer to a group of enzymes and proteins, such as DNA methyltransferases (DNMTs) and histone deacetylases (HDACs), that cooperatively regulate the chromatin state. In myeloid malignancies, these targets are often dysregulated due to somatic mutations in genes like DNMT3A, TET2, and IDH1/2, leading to a hypermethylated and condensed chromatin structure that silences genes essential for normal hematopoiesis (Ley et al., 2013, NEJM). Therapeutic intervention involves using combinations of hypomethylating agents and HDAC inhibitors to restore a transcriptionally active euchromatin state, which promotes the expression of tumor suppressors and triggers the differentiation or apoptosis of leukemic blasts (Garcia-Manero et al., 2020, Lancet Haematology). This multi-target strategy aims to overcome the limitations of single-agent epigenetic therapy, which often results in incomplete responses or drug resistance. By targeting the epigenetic machinery at multiple levels, clinicians hope to achieve deeper and more durable remissions in patients with high-risk AML and MDS. Monitoring for specific molecular biomarkers, such as IDH or DNMT3A mutations, is increasingly used to tailor these combined epigenetic approaches to individual patient profiles (Papaemmanuil et al., 2016, NEJM).

Other names

Combined epigenetic targetsEpigenetic modifiers in AML/MDSDNMT/HDAC combination targetsEpigenetic therapy targets

Synergistic reactivation of silenced tumor suppressor genes through the simultaneous inhibition of DNA methylation and histone deacetylation, leading to the restoration of normal hematopoietic differentiation pathways (Stahl et al., 2016, Cancer Discovery).